546 related articles for article (PubMed ID: 25209360)
1. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
Pelicano H; Zhang W; Liu J; Hammoudi N; Dai J; Xu RH; Pusztai L; Huang P
Breast Cancer Res; 2014 Sep; 16(5):434. PubMed ID: 25209360
[TBL] [Abstract][Full Text] [Related]
2. Metastatic TNBC is closely associated with a fused mitochondrial morphology and a glycolytic and lipogenic metabolism.
Pérez-Treviño P; Aguayo-Millán CD; Santuario-Facio SK; Vela-Guajardo JE; Salazar E; Camacho-Morales A; Ortiz R; García N
Biochem Cell Biol; 2021 Aug; 99(4):447-456. PubMed ID: 33342359
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
4. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming.
Jin J; Qiu S; Wang P; Liang X; Huang F; Wu H; Zhang B; Zhang W; Tian X; Xu R; Shi H; Wu X
J Exp Clin Cancer Res; 2019 Aug; 38(1):377. PubMed ID: 31455352
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
6. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
7. Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cao L; Niu Y
Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
[TBL] [Abstract][Full Text] [Related]
8. Anacardic Acid, Salicylic Acid, and Oleic Acid Differentially Alter Cellular Bioenergetic Function in Breast Cancer Cells.
Radde BN; Alizadeh-Rad N; Price SM; Schultz DJ; Klinge CM
J Cell Biochem; 2016 Nov; 117(11):2521-32. PubMed ID: 26990649
[TBL] [Abstract][Full Text] [Related]
9. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors.
Walsh S; Flanagan L; Quinn C; Evoy D; McDermott EW; Pierce A; Duffy MJ
Breast; 2012 Apr; 21(2):178-82. PubMed ID: 21963359
[TBL] [Abstract][Full Text] [Related]
10. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
Massihnia D; Galvano A; Fanale D; Perez A; Castiglia M; Incorvaia L; Listì A; Rizzo S; Cicero G; Bazan V; Castorina S; Russo A
Oncotarget; 2016 Sep; 7(37):60712-60722. PubMed ID: 27474173
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial dynamics as a novel treatment strategy for triple-negative breast cancer.
Wang Y; Harada-Shoji N; Kitamura N; Yamazaki Y; Ebata A; Amari M; Watanabe M; Miyashita M; Tada H; Abe T; Suzuki T; Gonda K; Ishida T
Cancer Med; 2024 Jan; 13(2):e6987. PubMed ID: 38334464
[TBL] [Abstract][Full Text] [Related]
12. FR58P1a; a new uncoupler of OXPHOS that inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway.
Urra FA; Muñoz F; Córdova-Delgado M; Ramírez MP; Peña-Ahumada B; Rios M; Cruz P; Ahumada-Castro U; Bustos G; Silva-Pavez E; Pulgar R; Morales D; Varela D; Millas-Vargas JP; Retamal E; Ramírez-Rodríguez O; Pessoa-Mahana H; Pavani M; Ferreira J; Cárdenas C; Araya-Maturana R
Sci Rep; 2018 Sep; 8(1):13190. PubMed ID: 30181620
[TBL] [Abstract][Full Text] [Related]
13. Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect.
Lu CL; Qin L; Liu HC; Candas D; Fan M; Li JJ
PLoS One; 2015; 10(3):e0121046. PubMed ID: 25807077
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
[TBL] [Abstract][Full Text] [Related]
15. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
18. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
